5Pauwels RA,Buist AS,Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Am J Respir Crit Care Med,2001,163:1256-1276. 被引量:1
6Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 1998,158:1277-1285. 被引量:1
7Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J, 1999,13:343-348. 被引量:1
8Sohy C, Pilette C, Niederman MS, et al. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed. Eur Respir J,2002,19:966-975. 被引量:1
9Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Immunoferon). Am J Repir Crit Care Med,2001,163:1578-1583. 被引量:1